Implementation of a pyridylcarbamoyl group and an isopropylpyridylsulfonamide substituent as key components in the scaffold of Bosentan resulted in the identification of the potent orally active endothelin receptor antagonist Ro 48-5695. It shows affinities for ETA and ETB receptors in the low nanomolar range and high functional antagonistic potency in vitro. (C) 1997 Elsevier Science Ltd.
Sulfonylaminopyrimidine, ihre Herstellung und Verwendung als Heilmittel